UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 167

Sortiert nach

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

Immunotherapy, 2020-04, Vol.12 (5), p.269

Bersanelli, Melissa

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years

Cancer Immunology, Immunotherapy, 2021-06, Vol.70 (6), p.1777-1780

2021

Link zum Volltext

Verfügbarkeit prüfen

Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer

Cancers, 2020-08, Vol.12 (8), p.2325

2020

Link zum Volltext

Verfügbarkeit prüfen

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.e121-e123

2016

Link zum Volltext

Verfügbarkeit prüfen

Tumour mutational burden as a driver for treatment choice in resistant tumours (and beyond)

The lancet oncology, 2020-10, Vol.21 (10), p.1255-1257

Bersanelli, Melissa

2020

Link zum Volltext

Verfügbarkeit prüfen

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

European journal of cancer (1990), 2020-03, Vol.128, p.17-26

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials

Human vaccines & immunotherapeutics, 2022-05, Vol.18 (3), p.1902723-1902723

2022

Link zum Volltext

Verfügbarkeit prüfen

The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient"

Human vaccines & immunotherapeutics, 2021-07, Vol.17 (7), p.1930-1934

2021

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

Therapeutic Advances in Medical Oncology, 2017-10, Vol.9 (10), p.627-636

2017

Link zum Volltext

Verfügbarkeit prüfen

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

Cancers, 2021-09, Vol.13 (18), p.4522

2021

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma

Human vaccines & immunotherapeutics, 2023-12, Vol.19 (1), p.2171672-2171672

2023

Link zum Volltext

Verfügbarkeit prüfen

Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

Scientific reports, 2019-09, Vol.9 (1), p.13218-13218, Article 13218

2019

Link zum Volltext

Verfügbarkeit prüfen

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

Therapeutic Advances in Medical Oncology, 2020, Vol.12, p.1758835920915303-1758835920915303

2020

Link zum Volltext

Verfügbarkeit prüfen

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis

Therapeutic advances in urology, 2021, Vol.13, p.17562872211053189-17562872211053189

2021

Link zum Volltext

Verfügbarkeit prüfen

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

Oncology Reviews, 2020-07, Vol.14 (2), p.490-490

2020

Link zum Volltext

Verfügbarkeit prüfen

Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?

Current oncology reports, 2021-12, Vol.23 (12), p.147-147, Article 147

2021

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

Scientific reports, 2020-02, Vol.10 (1), p.2304-2304, Article 2304

2020

Link zum Volltext

Verfügbarkeit prüfen

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

Therapeutic advances in urology, 2021, Vol.13, p.175628722110297-17562872211029784

2021

Link zum Volltext

Verfügbarkeit prüfen

Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report

Current drug targets, 2016-01, Vol.17 (15), p.1755

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical resistance predictors to first-line VEGFR-TKI monotherapy for metastatic renal cell carcinoma: a retrospective multicenter real-life case series

Journal of cancer metastasis and treatment, 2023, Vol.9, p.35

2023

Link zum Volltext

Verfügbarkeit prüfen

An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the ‘Pamerit’ study

Japanese journal of clinical oncology, 2021-03, Vol.51 (3), p.484-491

2021

Link zum Volltext

Verfügbarkeit prüfen

Avelumab Maintenance for Urothelial Carcinoma

The New England journal of medicine, 2020-12, Vol.383 (25), p.2482

2020

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 and the newly rediscovered multidisciplinarity

Immunotherapy, 2020-10, Vol.12 (15), p.1101

Bersanelli, Melissa

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 167

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(156)
Mit Volltextzugriff
(141)

Publikationsform

Sprache

Englisch
(167)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years

Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC

Tumour mutational burden as a driver for treatment choice in resistant tumours (and beyond)

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials

The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient"

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma

Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?

Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report

Clinical resistance predictors to first-line VEGFR-TKI monotherapy for metastatic renal cell carcinoma: a retrospective multicenter real-life case series

An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the ‘Pamerit’ study

Avelumab Maintenance for Urothelial Carcinoma

COVID-19 and the newly rediscovered multidisciplinarity

Suchergebnisse filtern